We Venture Capital, the venture capital arm of Werfen, focuses its investments on early-stage diagnostics start-ups, as well as digital solutions and biotechnology within the diagnostics space. Their strategy involves primarily investing in Seed, Series A, and Series B rounds for companies close to market or ready to scale, actively partnering with them globally to foster long-term growth.
67% of their portfolio is in Healthcare. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-a (100% of deals). Average disclosed round size is $19.2M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Respiree Pte Ltd | Series A | $11.6M | Jul 2025 |
 Portal Biotech | Series A | $35M | Jun 2025 |
| OOxford Cancer Analytics (OXcan) | Series A | $11M | Jan 2025 |
Top Co-Investors
Earlybird Venture Capital1 shared
8VC1 shared
SCVC1 shared
Pillar VC1 shared
Amino Collective1 shared
British Business Bank1 shared
WS Investment Company1 shared
ClavystBio1 shared
Adaptive Capital Partners1 shared
Seeds Capital1 shared
Civilization Ventures1 shared
Macmillan Cancer Support1 shared
OKG Investments1 shared
Last updated: 28 April 2026